Compounds > letrozole

letrozole and epirubicin

letrozole has been researched along with epirubicin in 11 studies

Research

Studies (11)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (27.27)29.6817
2010's7 (63.64)24.3611
2020's1 (9.09)2.80

Authors

AuthorsStudies
Lombardo, F; Obach, RS; Waters, NJ1
Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K1
Bagnardi, V; Balduzzi, A; Bertolini, F; Cardillo, A; Colleoni, M; Goldhirsch, A; Mancuso, P; Montagna, E; Orlando, L; Scarano, E; Torrisi, R; Veronesi, P; Viale, G1
Morimoto, N; Shibaki, T1
Amano, S; Enomoto, K; Sakurai, K1
Amano, S; Enomoto, K; Fujisaki, S; Hara, Y; Maeda, T; Nagashima, S; Sakurai, K; Shibata, M; Ueda, Y1
Barba, M; Del Medico, P; Di Lauro, L; Giannarelli, D; Laudadio, L; Maugeri-Saccà, M; Pizzuti, L; Sergi, D; Tomao, S; Vici, P1
Bassa, P; Capdevila, L; Garcia, JR; Pérez, C; Ramos, F; Valenti, V1
Cao, M; Deng, H; Liu, J; Rao, N; Wu, W; Yang, Y; You, N1
Chen, J; Deng, H; He, Z; Jin, L; Liu, J; Nie, Y; Rao, N; Su, F; Wu, W; Yang, Y; Yao, Y1

Reviews

1 review(s) available for letrozole and epirubicin

ArticleYear
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
    Drug discovery today, 2016, Volume: 21, Issue:4

    Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk

2016

Trials

2 trial(s) available for letrozole and epirubicin

ArticleYear
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: study protocol for a randomized pilot trial.
    Trials, 2017, Oct-25, Volume: 18, Issue:1

    Topics: Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Breast Neoplasms; Chemotherapy, Adjuvant; China; Clinical Protocols; Cyclophosphamide; Epirubicin; Everolimus; Feasibility Studies; Female; Fluorouracil; Humans; Letrozole; Lymphatic Metastasis; Neoadjuvant Therapy; Nitriles; Pilot Projects; Postmenopause; Receptor, ErbB-2; Receptors, Estrogen; Research Design; Treatment Outcome; Triazoles; Tumor Burden

2017
Neoadjuvant everolimus plus letrozole versus fluorouracil, epirubicin and cyclophosphamide for ER-positive, HER2-negative breast cancer: a randomized pilot trial.
    BMC cancer, 2021, Jul-27, Volume: 21, Issue:1

    Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Biopsy; Breast Neoplasms; Cyclophosphamide; Epirubicin; Everolimus; Female; Fluorouracil; Humans; Letrozole; Middle Aged; Pilot Projects; Receptor, ErbB-2; Receptors, Estrogen; Treatment Outcome

2021

Other Studies

8 other study(ies) available for letrozole and epirubicin

ArticleYear
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
    Drug metabolism and disposition: the biological fate of chemicals, 2008, Volume: 36, Issue:7

    Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding

2008
Physicochemical determinants of human renal clearance.
    Journal of medicinal chemistry, 2009, Aug-13, Volume: 52, Issue:15

    Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight

2009
Infusional fluorouracil, epirubicin, and cisplatin followed by weekly paclitaxel plus bevacizumab in locally advanced breast cancer with unfavorable prognostic features.
    Anti-cancer drugs, 2009, Volume: 20, Issue:3

    Topics: Adult; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carcinoma; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematologic Diseases; Humans; Hypertension; Infusions, Intravenous; Letrozole; Mastectomy; Middle Aged; Nitriles; Paclitaxel; Prognosis; Proteinuria; Radiotherapy, Adjuvant; Triazoles

2009
[A case of postoperative liver metastasis of mucinous carcinoma of the breast with complete response to sequential administration of FEC75, tamoxifen citrate, and letrozole].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:3

    Topics: Adenocarcinoma, Mucinous; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Letrozole; Liver Neoplasms; Mastectomy; Middle Aged; Nitriles; Tamoxifen; Triazoles

2010
[Indoleamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2010, Volume: 37, Issue:12

    Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Chemotherapy, Adjuvant; Chromatography, High Pressure Liquid; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Kynurenine; Letrozole; Middle Aged; Nitriles; Paclitaxel; Triazoles; Tryptophan

2010
[Long-term follow-up study: indolemamine 2,3-dioxygenase activity during chemotherapy or hormone therapy in patients with breast cancer].
    Gan to kagaku ryoho. Cancer & chemotherapy, 2011, Volume: 38, Issue:12

    Topics: Aged; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Cyclophosphamide; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Hormone Replacement Therapy; Humans; Indoleamine-Pyrrole 2,3,-Dioxygenase; Letrozole; Middle Aged; Nitriles; Paclitaxel; Time Factors; Triazoles

2011
Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer.
    Breast cancer research and treatment, 2013, Volume: 141, Issue:1

    Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Breast Neoplasms, Male; Carcinoma, Ductal, Breast; Carcinoma, Papillary; Chemotherapy, Adjuvant; Combined Modality Therapy; Cyclophosphamide; Disease-Free Survival; Docetaxel; Epirubicin; Estrogen Receptor Modulators; Estrogens; Fluorouracil; Gonadotropin-Releasing Hormone; Goserelin; Humans; Kaplan-Meier Estimate; Letrozole; Male; Mastectomy, Modified Radical; Methotrexate; Middle Aged; Neoplasms, Hormone-Dependent; Nitriles; Progesterone; Radiotherapy, Adjuvant; Tamoxifen; Taxoids; Triazoles

2013
18F-FDG PET/CT in the Staging and Management of Breast Cancer: Value in Disease Outcome and Planning Therapy.
    Clinical nuclear medicine, 2017, Volume: 42, Issue:3

    Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Aromatase Inhibitors; Axilla; Bone Density Conservation Agents; Bone Neoplasms; Breast Neoplasms; Chemotherapy, Adjuvant; Cyclophosphamide; Diphosphonates; Docetaxel; Epirubicin; Female; Fluorodeoxyglucose F18; Fluorouracil; Gonadotropin-Releasing Hormone; Humans; Imidazoles; Letrozole; Lymph Node Excision; Lymph Nodes; Mastectomy; Multimodal Imaging; Neoadjuvant Therapy; Neoplasm Staging; Nitriles; Positron Emission Tomography Computed Tomography; Radiopharmaceuticals; Radiotherapy; Ribs; Taxoids; Triazoles; Zoledronic Acid

2017